Review ArticleMinimally Invasive Surgical Staging in Early-stage Ovarian Carcinoma: A Systematic Review and Meta-analysis
Section snippets
Methods
The study search was designed to include population criteria, surgical interventions, and outcomes. Our systematic review was modeled according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement [7], and it was registered in the International Prospective Register of Systematic Reviews (available at http://www.crd.york.ac.uk/PROSPERO; CRD42016050582). As such, PubMed, Scopus, Web of Science, and EMBASE databases and ClinicalTrials.gov (www.clincaltrials.gov) were
Evidence Acquisition
Using the search criteria, 209 citations were initially identified. After applying the exclusion criteria, 11 publications remained 12, 13, 14, 15, 16, 17, 18, 19, 20, 21. Of the 11 comparative studies that met the inclusion criteria for this review, all were retrospective. Details of the process of evidence acquisition are displayed in Supplemental Figure 1. The included studies and their main characteristics are listed in Table 1. Overall, the 11 studies included 3065 patients. Specifically,
Discussion
This review article compares the current evidence on comparative studies evaluating MIS versus laparoscopy in the management of eEOC. Eleven retrospective studies including a total of 3065 patients show that MIS is associated with statistically better operative outcomes in comparison with open surgery. In fact, although the operative time is slightly (but not statistically significant) longer, patients undergoing laparoscopy experienced a lower estimated blood loss and a shorter length of
References (28)
- et al.
Laparoscopic management of early ovarian and fallopian tube cancers: surgical and survival outcome
Am J Obstet Gynecol
(2009) - et al.
Laparoscopic treatment of early ovarian cancer: surgical and survival outcomes
Gynecol Oncol
(2004) - et al.
Minimally invasive versus standard laparotomic interval debulking surgery in ovarian neoplasm: a single-institution retrospective case-control study
Gynecol Oncol
(2016) - et al.
Robotic radical hysterectomy in early stage cervical cancer: a systematic review and meta-analysis
Gynecol Oncol
(2015) - et al.
The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers
Am J Obstet Gynecol
(2005) - et al.
Laparoscopic versus laparotomic surgical staging for early-stage ovarian cancer: a case-control study
J Minim Invasive Gynecol
(2016) - et al.
Laparoscopic surgical staging in women with early stage epithelial ovarian cancer performed by recently certified gynecologic oncologists
Eur J Obstet Gynecol Reprod Biol
(2016) - et al.
Laparoscopic staging for apparent stage I epithelial ovarian cancer
Am J Obstet Gynecol
(2017) - et al.
Minimally invasive surgical staging for ovarian carcinoma: a propensity-matched comparison with traditional open surgery
J Minim Invasive Gynecol
(2017) - et al.
Laparoscopic restaging of early stage invasive adnexal tumors: a 10-year experience
Gynecol Oncol
(2004)
Laparoscopic fertility-sparing surgery for early ovarian epithelial cancer: a multi-institutional experience
Gynecol Oncol
Staging laparoscopy for the management of early-stage ovarian cancer: a metaanalysis
Am J Obstet Gynecol
Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study
J Clin Oncol
Laparoscopy versus laparotomy for FIGO stage I ovarian cancer
Cochrane Database Syst Rev
Cited by (49)
Prognostic value of lymph node ratio in patients with non-metastatic cervical cancer treated with radical hysterectomy: A population-based study
2024, European Journal of Surgical OncologyRobotic surgery in ovarian cancer
2023, Best Practice and Research: Clinical Obstetrics and GynaecologyRole of minimally invasive surgery in gynecologic malignancies
2023, DiSaia and Creasman Clinical Gynecologic OncologyOvarian clear cell carcinoma
2023, Diagnosis and Treatment of Rare Gynecologic CancersAssessing the role of minimally invasive radical hysterectomy for early-stage cervical cancer
2022, European Journal of Obstetrics and Gynecology and Reproductive Biology
Dr. Raspagliesi declared previous personal fees for serving on the board from Roche and PharmaMar. Dr. Lorusso declared previous grants and personal fees for board from PharmaMar and previous personal fees for board from Roche and AstraZeneca.